A pathway involving miR-600 and METTL3 is involved in the progression of non-small cell lung cancer (NSCLC), wherein miR-600 inhibits the expression of METTL3, thereby counteracting its positive effect on NSCLC progression. This evidence concerns the gene METTL3 and non-small cell lung carcinoma.